Skip to main content

Table 2 Genomic characteristics of patients with oncogene-driven mutations on TKI treatment

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Patient ID Age Gender Ethnicity Driver Oncogene Mutation PD-L1 IHC TMB TKI Treatment Clinical response RECIST V1.1 PFS (mos) OS (mos)
1 78 F Asian EGFR exon 19 deletion 0 NA Erlotinib, Osimertinib Good PR 16.2 32.8
2 72 F Asian EGFR L858R, EGFR T790M 2% 4 Erlotinib, Afatinib, Osimertinib Poor PD 7.7 46.6
3 76 F Asian EGFR L858R NA NA Gefitinib, Afatinib Good PR 7 25.3
4 73 F NHW EGFR exon 19 deletion 0 4 Afatinib, Osimertinib Good PR 16 19.9
5 79 F NHW ERBB2 L755 0 7 Afatinib Good PR 23.9 38.4
6 43 M Asian EGFR exon 19 deletion 50% 4 Osimertinib Poor PD 0.7 7.8
7 69 M NHW EGFR L858R, EGFR T790M 30% 6 Osimertinib Poor PD 4.5 14.5
8 76 F H EGFR L858R, EGFR T790M, C797S 5% 5 Afatinib, Brigatinib Poor PD 2 3.9
9 57 F Asian EGFR L858R, EGFR T790M 0 8 Osimertinib Poor PR 20.4 21.5
10 85 F Asian EGFR L858R, EGFR T790M 0 9 Osimertinib Poor PR 4.4 6.5
11 55 M Asian EGFR exon 19 deletion 0 7.4 Osimertinib Good SD 21 33
12 68 F NHW EGFR exon 19 deletion 70% 7 Osimertinib Poor SD 0.9 7.9
13 67 F NHW EGFR L858R 100% 16 Osimertinib Poor SD 6 6
14 79 M Asian EGFR L858R 0 2 Erlotinib Good PR 10.5 26.2
15 79 M Asian EGFR L858R, EGFR T790M 0 2 Osimertinib Good PR 105 26.2
16 53 F Asian EGFR exon 19 deletion 50% 4 Erlotinib Good PR 25.1 49
17 82 F Asian METTL25-ALK fusion 15% 2 Alectinib Good PR 37 37
18 73 M Asian MET amplification 30% 14 Crizotinib Good PR 10.6 10.7
19 45 M Asian EML4-ALK V3a/b fusion 50% 6 Alectinib Good PR 16 38.4
20 64 M NHW EGFR exon 19 deletion 1% 4 Osimertinib Good PR 12.6 21.3
21 58 M Asian EML4-ALK V4a/b fusion 50% 0 Alectinib Good PR 60.6 60.6
22 60 F Asian KIF5b-RET fusion 80% 0 Alectinib Poor PD 6.2 14.1
23 79 F NHW EGFR exon 20 insertion 10% 7.4 Poziotinib Good PD 8.7 18.6
24 72 F NHW EGFR exon 20 insertion 0 3.7 Osimertinib Poor PD 3.7 3.7
25 56 F Asian EGFR exon 19 deletion > 1% 6.3 Osimertinib Poor PD 2.1 2.1
26 59 F NHW EGFR L858R 8% 2.5 Osimertinib Poor SD 10 15.9
27 51 F Asian EGFR exon 19 deletion 6% 11.6 Osimertinib Poor PD 3.9 3.9
28 61 F NHW CCDC6-RET fusion 0 2.6 Selpercatinib Good SD 5.8 5.8
29 59 M NHW HER2 amplification 0 9.5 Afatinib Good SD 8 8
30 69 F NHW MET exon 14 mutation 25% 11 Campactinib Good PR 1.9 1.9
31 66 F NHW CD47-MET fusion; MET missense mutation 0 1.1 Campactinib Good PR 1.5 1.5
32 73 M NHW EGFR exon 19 deletion 0 1 Osimertinib Good PR 6.3 9.5
33 74 M NHW ERBB2 exon 20 insertion 0 3.2 Poziotinib Poor PD 1.6 18.1
34 79 F NHW EGFR Exon 20 insertion 10% 7.4 Osimertinib Poor PD 4.1 18.6